Codexis (CDXS) Competitors

Codexis (NASDAQ:CDXS) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Do analysts prefer CDXS or GERN?

Codexis currently has a consensus price target of $8.00, indicating a potential upside of 223.23%. Geron has a consensus price target of $5.06, indicating a potential upside of 240.91%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Geron	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

Does the MarketBeat Community favor CDXS or GERN?

Geron received 149 more outperform votes than Codexis when rated by MarketBeat users. Likewise, 69.93% of users gave Geron an outperform vote while only 61.36% of users gave Codexis an outperform vote.

Company	Underperform	Outperform
Codexis	Outperform Votes 351 61.36%	Underperform Votes 221 38.64%
Geron	Outperform Votes 500 69.93%	Underperform Votes 215 30.07%

Do insiders & institutionals have more ownership in CDXS or GERN?

78.5% of Codexis shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 2.1% of Codexis shares are owned by company insiders. Comparatively, 7.4% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher earnings & valuation, CDXS or GERN?

Codexis has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$59.35M	3.46	-$76.24M	-$0.99	-2.50
Geron	$116.29M	8.13	-$184.13M	-$0.21	-7.07

Which has more volatility and risk, CDXS or GERN?

Codexis has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Does the media refer more to CDXS or GERN?

In the previous week, Codexis and Codexis both had 11 articles in the media. Geron's average media sentiment score of 1.02 beat Codexis' score of 0.03 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CDXS or GERN more profitable?

Codexis has a net margin of -96.35% compared to Geron's net margin of -682.48%. Geron's return on equity of -67.53% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-96.35%	-71.56%	-38.00%
Geron	-682.48%	-67.53%	-45.46%

Summary

Geron beats Codexis on 12 of the 18 factors compared between the two stocks.